Literature DB >> 12548704

Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons.

Tomoki Nakamizo1, Jun Kawamata, Kohei Yoshida, Yuko Kawai, Rie Kanki, Hideyuki Sawada, Takeshi Kihara, Hirofumi Yamashita, Hiroshi Shibasaki, Akinori Akaike, Shun Shimohama.   

Abstract

We have previously reported that cyclic guanosine-3',5'-monophosphate (cGMP) protects spinal motor neurons against acute reactive oxygen species (ROS)-induced toxicity but not against chronic ROS-induced or glutamate (Glu)-induced toxicity. In this study, we investigated the effects of phosphodiesterase (PDE) inhibitors on the survival of cultured spinal motor neurons. Selective PDE5 inhibitors (dipyridamole, T-1032, and zaprinast) as well as a nonselective PDE inhibitor (aminophylline) protected motor and nonmotor neurons against both acute ROS-induced and chronic Glu-induced neurotoxicity, whereas selective inhibitors of PDE1-4 offered no protection. 8-Bromo-cGMP (8br-cGMP), a cGMP analogue, protected both motor and nonmotor neurons against acute ROS-induced toxicity but protected only nonmotor neurons against chronic Glu-induced toxicity. This neuroprotection was blocked by KT5823, a cGMP-dependent protein kinase (PKG) inhibitor. Immunohistochemical staining confirmed that PDE5 and PKG are located in almost all rat lumbar spinal neurons. Furthermore, semiquantitative analysis of the immunostaining intensity revealed that PDE5 was more abundant in motor neurons than in nonmotor neurons. Our results suggest that this difference in the amount of PDE5 may be responsible for the vulnerability of motor neurons to chronic excitotoxicity. In addition, the results of this study raise the possibility that PDE5 inhibitors might be used as a treatment for amyotrophic lateral sclerosis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548704     DOI: 10.1002/jnr.10483

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  15 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  Neuroprotective effects of sildenafil in experimental spinal cord injury in rabbits.

Authors:  Hasan Kara; Selim Degirmenci; Ahmet Ak; Aysegul Bayir; Seyit Ali Kayis; Mehmet Uyar; Murat Akinci; Demet Acar; Metin Kocacan; Fikret Akyurek
Journal:  Bosn J Basic Med Sci       Date:  2015-01-08       Impact factor: 3.363

3.  C-type natriuretic peptide functions as an innate neuroprotectant in neonatal hypoxic-ischemic brain injury in mouse via natriuretic peptide receptor 2.

Authors:  Qingyi Ma; Lubo Zhang
Journal:  Exp Neurol       Date:  2018-03-05       Impact factor: 5.330

4.  Protein Kinase G facilitates EGFR-mediated cell death in MDA-MB-468 cells.

Authors:  Nicole M Jackson; Brian P Ceresa
Journal:  Exp Cell Res       Date:  2016-07-02       Impact factor: 3.905

5.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

6.  Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice.

Authors:  Anbrin Masood; Ahmed Nadeem; S Jamal Mustafa; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2008-05-02       Impact factor: 4.030

7.  Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanisms.

Authors:  Lianshu Ding; Chong Zhang; Anbrin Masood; Jianxin Li; Jiao Sun; Ahmed Nadeem; Han-Ting Zhang; James M O' Donnell; Ying Xu
Journal:  Behav Brain Res       Date:  2014-03-30       Impact factor: 3.332

8.  Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy.

Authors:  Ana-Maria Oprişoreanu; Hannah L Smith; Sophia Krix; Helena Chaytow; Neil O Carragher; Thomas H Gillingwater; Catherina G Becker; Thomas Becker
Journal:  Dis Model Mech       Date:  2021-04-26       Impact factor: 5.758

9.  Disease-associated mutations in CNGB3 promote cytotoxicity in photoreceptor-derived cells.

Authors:  Chunming Liu; Tshering Sherpa; Michael D Varnum
Journal:  Mol Vis       Date:  2013-06-11       Impact factor: 2.367

Review 10.  Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.

Authors:  Sharron H Francis; Jackie D Corbin
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.